<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022563</url>
  </required_header>
  <id_info>
    <org_study_id>X9001305</org_study_id>
    <secondary_id>VTE HIRA Study</secondary_id>
    <nct_id>NCT05022563</nct_id>
  </id_info>
  <brief_title>Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea</brief_title>
  <official_title>Treatment Patterns and Clinical Outcomes Among Venous Thromboembolism Patients Treated With Anticoagulants After the Entry of Non-vitamin K Antagonist Oral Anticoagulants in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a retrospective, observational, nationwide population-based cohort study&#xD;
      utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.&#xD;
      The aims of this study are to describe the sociodemographic and clinical characteristics of&#xD;
      patients with venous thromboembolism according to their anticoagulant treatment (parenteral&#xD;
      anticoagulants, warfarin, or non-vitamin K antagonist oral anticoagulants), to describe the&#xD;
      treatment patterns related to anticoagulants, and to examine the risk of major bleeding&#xD;
      according to the specific type of oral anticoagulants. The study will be conducted in two&#xD;
      phases: Phase I for descriptive study and Phase II for comparative study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment interruption</measure>
    <time_frame>From index date to follow-up period (up to a maximum duration of 81 months)</time_frame>
    <description>Treatment interruption is defined as when a patient has a gap with no new treatment within 30 days of the estimated end of supply, but subsequently restarts the index treatment after this period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment switch</measure>
    <time_frame>From index date to follow-up period (up to a maximum duration of 81 months)</time_frame>
    <description>Treatment switching is defined as a prescription of another anticoagulant therapy that is started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment discontinuation</measure>
    <time_frame>From index date to follow-up period (up to a maximum duration of 81 months)</time_frame>
    <description>Complete discontinuation; no reinitiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median overall treatment duration for index treatment</measure>
    <time_frame>From index date to follow-up period (up to a maximum duration of 81 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event rate of major bleeding</measure>
    <time_frame>From index date to follow-up period (up to a maximum duration of 81 months)</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Parenteral anticoagulant only</arm_group_label>
    <description>LMWH, UFH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin-based</arm_group_label>
    <description>Warfarin only + parenteral anticoagulant bridged warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parenteral anticoagulant / NOAC</arm_group_label>
    <description>NOAC: apixaban, rivaroxban, dabigatran, edoxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOAC only</arm_group_label>
    <description>NOAC: apixaban, rivaroxban, dabigatran, edoxaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parenteral anticoagulant</intervention_name>
    <description>Parenteral anticoagulant only</description>
    <arm_group_label>Parenteral anticoagulant only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin-based</description>
    <arm_group_label>Warfarin-based</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Apixaban</description>
    <arm_group_label>NOAC only</arm_group_label>
    <arm_group_label>Parenteral anticoagulant / NOAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban</description>
    <arm_group_label>NOAC only</arm_group_label>
    <arm_group_label>Parenteral anticoagulant / NOAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran</description>
    <arm_group_label>NOAC only</arm_group_label>
    <arm_group_label>Parenteral anticoagulant / NOAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Edoxaban</description>
    <arm_group_label>NOAC only</arm_group_label>
    <arm_group_label>Parenteral anticoagulant / NOAC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with venous thromboembolism from the South Korea's Health Insurance&#xD;
        Review and Assessment Service (HIRA) database between Mar 1, 2013 and Jun 30, 2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Incident VTE diagnosis in an inpatient or outpatient setting between 1 Mar 2013 and 30&#xD;
             Jun 2019&#xD;
&#xD;
          2. Received anticoagulation therapy (all medication codes for anticoagulants approved for&#xD;
             VTE in Korea; UFH, LMWH, warfarin, and NOACs) within 30 days of their VTE diagnosis&#xD;
             (the index date will be defined as the date of treatment initiation with&#xD;
             anticoagulants)&#xD;
&#xD;
          3. Aged â‰¥18 years at index date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had a record of VTE diagnosis within the 12-month period prior to the index VTE&#xD;
             encounter.&#xD;
&#xD;
          2. Diagnosed with atrial fibrillation/flutter, mechanical heart valve replacement or&#xD;
             mitral stenosis anytime prior to index date&#xD;
&#xD;
          3. Had a record of Inferior Vena Cava filter anytime prior to index date&#xD;
&#xD;
          4. Received anticoagulatory therapy within the 12-month period prior to index VTE&#xD;
             encounter&#xD;
&#xD;
          5. Prescribed two different anticoagulants on the same index date&#xD;
&#xD;
          6. Had a record of pregnancy within the 9-month period prior to index date&#xD;
&#xD;
          7. Had a record of active cancer within the past 6 months of period prior to index date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sungkyunkwan University</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>treatment pattern</keyword>
  <keyword>bleed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

